Anti-PD-1 and Anti-M-CSF Antibody Combination for Resistant Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for solid tumors and triple-negative breast cancer, are inadequate due to intrinsic and acquired resistance to checkpoint inhibitors, necessitating the development of novel combination therapies that can effectively target resistant cancer types.
Innovation Solution
A combination of a macrophage colony stimulating factor (M-CSF) antagonist and a Programmed Death 1 (PD-1) antagonist, administered separately or together, to enhance T cell antitumor responses by blocking immunosuppressive signals and rescuing exhausted T cells, thereby targeting resistant or refractory cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) are used to treat cancer, then immune response against tumor is enhanced, but intrinsic and acquired resistance develops leading to treatment failure
Solution Approach 1:
The patent combines anti-PD-1/PD-L1 antibodies with anti-CTLA-4 antibodies to create a combination immunotherapy regimen. This merging of two different checkpoint inhibition mechanisms addresses resistance to single-agent therapy by targeting multiple immune checkpoint pathways simultaneously, thereby overcoming both intrinsic and acquired resistance to checkpoint inhibitors alone.
Solution Approach 2:
The invention creates a composite therapeutic approach by integrating two distinct monoclonal antibody therapies (anti-PD-1/PD-L1 and anti-CTLA-4) into a unified treatment protocol. This composite strategy leverages the complementary mechanisms of action of both antibodies to achieve enhanced and sustained antitumor immunity that overcomes resistance to either agent alone.
2Reliability
If combination therapies are developed to overcome resistance, then treatment effectiveness improves, but therapy complexity increases
Solution Approach 1:
The patent merges anti-PD-1/PD-L1 and anti-CTLA-4 therapies into a coordinated combination regimen with defined dosing schedules and administration protocols. By establishing standardized combination protocols, the patent reduces the practical complexity of delivering effective combination therapy while maintaining enhanced treatment effectiveness against resistant cancers.
Data Source
Figure 1
AI summary
The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.